Multi-omics subgroups associated with glycaemic deterioration in type 2 diabetes: an IMI-RHAPSODY Study

• Published in: Frontiers in endocrinology (Lausanne) Vol. 15; p. 1350796
• Main Authors: Li, Shiying, Dragan, Iulian, Tran, Van Du T., Fung, Chun Ho, Kuznetsov, Dmitry, Hansen, Michael K., Beulens, Joline W. J., Hart, Leen M. ‘t, Slieker, Roderick C., Donnelly, Louise A., Gerl, Mathias J., Klose, Christian, Mehl, Florence, Simons, Kai, Elders, Petra J. M., Pearson, Ewan R., Rutter, Guy A., Ibberson, Mark
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 06.03.2024
• Subjects: Diabetes Mellitus, Type 2 - metabolism; Endocrinology; glycaemic deterioration; Humans; Insulin Resistance; lipidomics; metabolic syndrome; multi-omics; Multiomics; Proteomics; type 2 diabetes; metabolic syndrome; multi-omics; glycaemic deterioration; type 2 diabetes; proteomics; lipidomics
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2024.1350796

Type 2 diabetes (T2D) onset, progression and outcomes differ substantially between individuals. Multi-omics analyses may allow a deeper understanding of these differences and ultimately facilitate personalised treatments. Here, in an unsupervised "bottom-up" approach, we attempt to group T2D patients based solely on -omics data generated from plasma. Circulating plasma lipidomic and proteomic data from two independent clinical cohorts, Hoorn Diabetes Care System (DCS) and Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS), were analysed using Similarity Network Fusion. The resulting patient network was analysed with Logistic and Cox regression modelling to explore relationships between plasma -omic profiles and clinical characteristics. From a total of 1,134 subjects in the two cohorts, levels of 180 circulating plasma lipids and 1195 proteins were used to separate patients into two subgroups. These differed in terms of glycaemic deterioration (Hazard Ratio=0.56;0.73), insulin sensitivity and secretion (C-peptide, =3.7e-11;2.5e-06, DCS and GoDARTS, respectively; Homeostatic model assessment 2 (HOMA2)-B; -IR; -S, p=0.0008;4.2e-11;1.1e-09, only in DCS). The main molecular signatures separating the two groups included triacylglycerols, sphingomyelin, testican-1 and interleukin 18 receptor. Using an unsupervised network-based fusion method on plasma lipidomics and proteomics data from two independent cohorts, we were able to identify two subgroups of T2D patients differing in terms of disease severity. The molecular signatures identified within these subgroups provide insights into disease mechanisms and possibly new prognostic markers for T2D.